This article is more than 5 years old. Information may no longer be current.
REDUCE: Coronary artery disease potential risk factor for prostate cancer
Thomas JA. Cancer Epidemiol Biomarkers Prev. 2012;doi:10.1158/1055-9965.EPI-11-1017.
Men with coronary artery disease had a 35% increased risk for prostate cancer, according to a secondary analysis of 4-year results from the REDUCE trial.
“What’s good for the heart may be good for the prostate,” study researcher Jean-Alfred Thomas II, MD, a postdoctoral fellow in the division of urology at Duke University School of Medicine, said in a press release. “We don’t have a good grasp on what’s causing the link, but we are observing this association.”
In REDUCE, a multicenter, double blind, placebo-controlled study, men (n=8,122) at elevated risk for prostate cancer were assigned to 0.5 mg daily dutasteride (Avodart, GlaxoSmithKline). Eligible participants had a PSA of 2.5 ng/mL to 10 ng/mL and a negative biopsy within 6 months of enrollment.
There were 547 men in the study with a history of coronary artery disease. Those men tended to be older, heavier, more likely to have diabetes, and have higher PSA and large prostate volumes. These men also were more likely to have hypertension and hypercholesterolemia, and to have taken aspirin or a statin.
Multivariate analysis showed that coronary artery disease was associated with a 35% increased risk for prostate cancer (OR=1.35; 95% CI, 1.08-1.67). Coronary artery disease was similarly associated with an elevated risk for low-grade prostate cancer (OR=1.34; 95% CI, 1.05-1.73) and high-grade disease (OR=1.34; 95% CI, 0.95-1.88).
After adjusting for potential confounders, men with coronary artery disease were 24% more likely to be diagnosed with prostate cancer at 2 years (OR=1.24; 95% CI, 0.96-1.59) and 73% more likely to be diagnosed with prostate cancer at 4 years (OR=1.73, 95% CI, 1.23-2.43).
 |
Follow HemOncToday.com on Twitter. |